Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease

Hdl Handle:
http://hdl.handle.net/10147/333615
Title:
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
Authors:
Dowling, Paul; Hayes, Catriona; Ting, Kay R; Hameed, Abdul; Meiller, Justine; Mitsiades, Constantine; Anderson, Kenneth C; Clynes, Martin; Clarke, Colin; Richardson, Paul; O’Gorman, Peter
Citation:
BMC Genomics. 2014 Oct 17;15(1):904
Issue Date:
17-Oct-2014
URI:
http://dx.doi.org/10.1186/1471-2164-15-904; http://hdl.handle.net/10147/333615
Abstract:
Abstract Background Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients develop osteolytic bone lesions associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Biomarkers of bone remodelling are used to identify disease characteristics that can help select the optimal management of patients. However, more accurate biomarkers are needed to effectively mirror the dynamics of bone disease activity. Results A label-free mass spectrometry-based strategy was employed for discovery phase analysis of fractionated patient serum samples associated with no or high bone disease. A number of proteins were identified which were statistically significantly correlated with bone disease, including enzymes, extracellular matrix glycoproteins, and components of the complement system. Conclusions Enzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1 indicated that these proteins were associated with high bone disease in a larger independent cohort of patient samples. These biomolecules may therefore be clinically useful in assessing the extent of bone disease.
Item Type:
Article
Language:
en
Keywords:
BONE DENSITY
Local subject classification:
BONE DISEASE; GENOMICS

Full metadata record

DC FieldValue Language
dc.contributor.authorDowling, Paulen_GB
dc.contributor.authorHayes, Catrionaen_GB
dc.contributor.authorTing, Kay Ren_GB
dc.contributor.authorHameed, Abdulen_GB
dc.contributor.authorMeiller, Justineen_GB
dc.contributor.authorMitsiades, Constantineen_GB
dc.contributor.authorAnderson, Kenneth Cen_GB
dc.contributor.authorClynes, Martinen_GB
dc.contributor.authorClarke, Colinen_GB
dc.contributor.authorRichardson, Paulen_GB
dc.contributor.authorO’Gorman, Peteren_GB
dc.date.accessioned2014-11-04T10:15:30Z-
dc.date.available2014-11-04T10:15:30Z-
dc.date.issued2014-10-17-
dc.identifier.citationBMC Genomics. 2014 Oct 17;15(1):904en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2164-15-904-
dc.identifier.urihttp://hdl.handle.net/10147/333615-
dc.description.abstractAbstract Background Bone destruction is a feature of multiple myeloma, characterised by osteolytic bone destruction due to increased osteoclast activity and suppressed or absent osteoblast activity. Almost all multiple myeloma patients develop osteolytic bone lesions associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Biomarkers of bone remodelling are used to identify disease characteristics that can help select the optimal management of patients. However, more accurate biomarkers are needed to effectively mirror the dynamics of bone disease activity. Results A label-free mass spectrometry-based strategy was employed for discovery phase analysis of fractionated patient serum samples associated with no or high bone disease. A number of proteins were identified which were statistically significantly correlated with bone disease, including enzymes, extracellular matrix glycoproteins, and components of the complement system. Conclusions Enzyme-linked immunosorbent assay of complement C4 and serum paraoxonase/arylesterase 1 indicated that these proteins were associated with high bone disease in a larger independent cohort of patient samples. These biomolecules may therefore be clinically useful in assessing the extent of bone disease.-
dc.language.isoenen
dc.subjectBONE DENSITYen_GB
dc.subject.otherBONE DISEASEen_GB
dc.subject.otherGENOMICSen_GB
dc.titleIdentification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone diseaseen_GB
dc.typeArticleen
dc.language.rfc3066en-
dc.rights.holderPaul Dowling et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2014-10-27T12:03:47Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.